NEW YORK (GenomeWeb) – Personal Genome Diagnostics said today that it is moving forward with the development of a novel diagnostic to help identify which cancer patients are most likely to benefit from treatment with immune checkpoint inhibitors under an SBIR contract awarded by the National Institutes of Health late last year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.